89bio, Inc.

Equities

ETNB

US2825591033

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
8.18 ^USD	-8.40%		-8.81%	-26.77%

05-14	89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	CI
05-10	HC Wainwright Adjusts 89bio's Price Target to $29 From $31, Maintains Buy Rating	MT

89bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 10, 2023 at 01:06 pm

89bio, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 102.03 million compared to USD 90.12 million a year ago. Basic loss per share from continuing operations was USD 2.93 compared to USD 4.48 a year ago.

Latest news about 89bio, Inc.

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	05-14	CI
HC Wainwright Adjusts 89bio's Price Target to $29 From $31, Maintains Buy Rating	05-10	MT
89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
89bio, Inc. Appoints Martin Babler to Its Board of Directors	04-17	CI
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	04-03	MT
Sector Update: Health Care Stocks Gain Wednesday Afternoon	03-27	MT
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	03-27	MT
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	03-27	CI
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	03-12	CI
North American Morning Briefing : Stock Futures -2-	03-08	DJ
Evercore ISI Adjusts 89bio Price Target to $37 From $29, Maintains Outperform Rating	03-07	MT
Top Premarket Gainers	03-04	MT
HC Wainwright Cuts Price Target on 89bio to $31 From $32, Keeps Buy Rating	03-01	MT
RBC Trims Price Target on 89bio to $14 From $15, Keeps Sector Perform, Speculative Risk	03-01	MT
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29	CI
North American Morning Briefing : Stock Futures -2-	01-16	DJ
RBC Downgrades 89bio to Sector Perform From Outperform, Cuts Price Target to $15 From $24 on View for 'Quieter Year,' Keeps Speculative Risk	01-12	MT
89bio Insider Sold Shares Worth $560,000, According to a Recent SEC Filing	01-03	MT
HC Wainwright Cuts 89bio Price Target to $32 From $35, Maintains Buy Rating	12-20	MT
89bio Prices Upsized $150 Million Offering of Common Shares, Pre-Funded Warrants	12-07	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	12-07	MT
89bio Launches $125 Million Offering of Common Shares, Pre-Funded Warrants	12-07	MT
Sector Update: Health Care Stocks Rise Late Afternoon	12-04	MT
Sector Update: Health Care Stocks Rise Monday Afternoon	12-04	MT
89bio Share Rise on Advance Into Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	12-04	MT

Chart 89bio, Inc.

Duration

Period

More charts

Company Profile

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Companyâs lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.

Sector

Biotechnology & Medical Research

Calendar

29/05/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.18 USD

Average target price

31.11 USD

Spread / Average Target

+280.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
89BIO, INC.	-26.77%	805M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	116B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	23.89B
ARGENX SE	-3.46%	21.58B
GENMAB A/S	-9.54%	18.96B
BEIGENE, LTD.	-13.41%	16.33B
WUXI APPTEC CO., LTD.	-40.50%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.14B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.02B

Bio Therapeutic Drugs